Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Enveric Biosciences, Inc. (ENVB) had Consolidated Net Income/Loss of $-1.87M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-3.39M |
|
-- |
|
-- |
|
$1.87M |
|
$-1.87M |
|
$0.00M |
|
$-1.87M |
|
$-1.87M |
|
$-1.87M |
|
$-1.87M |
|
|
Consolidated Net Income/Loss |
$-1.87M |
$-1.87M |
|
$-1.87M |
|
$-1.83M |
|
0.31M |
|
0.31M |
|
$-10.81 |
|
$-10.81 |
|
| Balance Sheet Financials | |
$4.17M |
|
$0.20M |
|
$0.20M |
|
$4.36M |
|
$0.91M |
|
-- |
|
-- |
|
$0.91M |
|
$3.46M |
|
$3.46M |
|
$3.46M |
|
0.52M |
|
| Cash Flow Statement Financials | |
$-6.36M |
|
-- |
|
$7.89M |
|
$2.24M |
|
$3.76M |
|
$1.52M |
|
$0.59M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.21% |
|
-54.21% |
|
-42.95% |
|
-54.21% |
|
$6.67 |
|
$-20.29 |
|
$-20.29 |
|